Literature DB >> 2972545

The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting.

L D de Haan, P H de Mulder, L V Beex, F M Debruyne, T Challoner, B E de Pauw.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2972545     DOI： 10.1016/0277-5379(88)90235-0

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN： 0277-5379


× No keyword cloud information.
  6 in total

1.  Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors.

Authors:  A Hamik; S J Peroutka
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

2.  Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan.

Authors:  C V Viner; P J Selby; G B Zulian; M E Gore; M E Butcher; C M Wootton; T J McElwain
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  5-HT3 antagonist ondansetron--an effective outpatient antiemetic in cancer treatment.

Authors:  C R Pinkerton; D Williams; C Wootton; S T Meller; T J McElwain
Journal:  Arch Dis Child       Date:  1990-08       Impact factor: 3.791

Review 4.  Antiemetics in cancer chemotherapy: historical perspective and current state of the art.

Authors:  M Tonato; F Roila; A Del Favero; E Ballatori
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

Review 5.  [Management of chemotherapy-induced emesis: what is the standard after 20 years of clinical research].

Authors:  A Du Bois
Journal:  Med Klin (Munich)       Date:  1998-01

Review 6.  Reducing chemotherapy-induced nausea and vomiting. Current perspectives and future possibilities.

Authors:  A Del Favero; F Roila; M Tonato
Journal:  Drug Saf       Date:  1993-12       Impact factor: 5.606
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.